Arrowstreet Capital
CAI

Arrowstreet Capital’s Caris Life Sciences CAI Stock Holding History

Arrowstreet Capital’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Buy
655,644
+445,051
+211% +$7.97M 0.01% 1024
2026
Q1 		$3.77M Buy
+210,593
New +$4.6M ﹤0.01% 1244

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arrowstreet Capital's CAI Position: Q2 2026 in Review

Arrowstreet Capital increased its Caris Life Sciences (CAI) stake by 211% in Q2 2026, buying an estimated $7.97M and bringing the position to 655,644 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #1024.

Arrowstreet Capital first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Arrowstreet Capital held 655,644 shares of Caris Life Sciences worth $11.7M as of Q2 2026.
  • Arrowstreet Capital bought 445,051 Caris Life Sciences shares in Q2 2026, an estimated $7.97M.
  • Caris Life Sciences made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1024 holding.
  • Arrowstreet Capital first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.